CH373759A - Process for the production of a new heart-acting salt - Google Patents

Process for the production of a new heart-acting salt

Info

Publication number
CH373759A
CH373759A CH8137559A CH8137559A CH373759A CH 373759 A CH373759 A CH 373759A CH 8137559 A CH8137559 A CH 8137559A CH 8137559 A CH8137559 A CH 8137559A CH 373759 A CH373759 A CH 373759A
Authority
CH
Switzerland
Prior art keywords
methyl
heptanol
production
salt
acid
Prior art date
Application number
CH8137559A
Other languages
German (de)
Inventor
Jakob Dr Schenk
Aldo Dr Ing Chem Riva
Original Assignee
Wander Ag Dr A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wander Ag Dr A filed Critical Wander Ag Dr A
Priority to CH8137559A priority Critical patent/CH373759A/en
Publication of CH373759A publication Critical patent/CH373759A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  
 



  Verfahren zur Herstellung eines neuen herzwirksamen Salzes
Aus der deutschen Patentschrift Nr. 352980 ist es bekannt, dass N-Alkylcarbonsäuren dialkylierter Xanthine in Wasser leicht lösliche, neutral reagierende Salze mit therapeutischer Wirkung liefern.



   Anderseits ist es bekannt, dass Aminoalkohole mit tertiärer Hydroxylgruppe der Formel
EMI1.1     
 worin R Wasserstoff oder eine Methylgruppe ist, interessante therapeutische Eigenschaften als Cardiotonika besitzen (Loubatieres A., Arch. int. pharmacodyn. 85, 333   L1951J,    Robert P. Walton  &  Oliver J Brodie, Journ. of Pharmacol.  &  Exptl. Therapeutics, Vol. 96, Nr. 4, August 1949). Die genannten Aminoalkohole stellen Flüssigkeiten dar, welche mit verschiedenen Säuren Salze bilden. Verwendet wurde insbesondere das Hydrochlorid, welches jedoch den Nachteil hat, dass es bei Injektion in höheren Konzentrationen Nekrosen verursacht.



   Es wurde nun gefunden, dass die genannten Aminoalkohole mit N-Alkyl-carbonsäuren dialkylierter Xanthine Salze liefert, die in Wasser neutrale Lösungen ergeben, welche ohne Nachteil auch in hohen Konzentrationen injiziert werden können, wobei die beiden an sich bekannten Komponenten des Salzes eine überraschend günstige therapeutische Kombinationswirkung ergeben. Diese Wirkung tritt auch bei oraler Verabreichung auf.



   Die Salzbildung kann in der üblichen Weise durch Umsetzen des   6-Amino 2- methyl-2-heptanols    bzw.



     6 -Methylamino- 2-methyl-2 -heptanols    mit der N Alkylcarbonsäure eines dialkylierten Xanthins in einem geeigneten Lösungsmittel wie   Athanol    oder Chloroform, vorzugsweise unter leichtem Erwärmen erfolgen.



   Die gebildeten Salze sind neue Verbindungen mit günstigen Applikationseigenschaften und vorzüglicher therapeutischer Wirkung.



   Beispiel 1
14,5 g 6-Amino-2-methyl-2-heptanol, in 100   ml    Äthylalkohol gelöst, werden mit 24 g Theophyllin-7essigsäure (hergestellt durch Reaktion von Natriumtheophyllinat mit Natriummonochloracetat) versetzt.



  Unter Rühren und gelindem Erwärmen geht die Säure vollständig in Lösung. Die klare Lösung wird bei   0"    über Nacht stehengelassen; es scheidet sich eine feine schneeweisse kristalline Masse aus, die nach Filtration und Waschen mit kaltem Alkohol bei 600 C im Vakuum getrocknet wird. Ausbeute: 35 g =   91%.   



   Das (6-Amino-2-methyl-2-heptanol)-theophyllinacetat ist ein weisses kristallines, praktisch geruchloses Pulver. Es ist in Wasser mit neutraler Reaktion sehr leicht löslich, wenig löslich in Alkohol und sehr wenig in Äther.



   Schmelzpunkt:   140-142     C (korr.).



   Beispiel 2
15,9 g   6-Methylamino - 2 - methyl-2-heptanol    und 24 g Theophyllinessigsäure werden wie im Beispiel 1 reagieren gelassen. Man erhält das (6-Methylamino2-methyl-2-heptanol)-theophyllinacetat als ein weisses kristallines Pulver mit Schmelzpunkt   114-116  C.   



  Das Salz ist in Wasser mit neutraler Reaktion leicht löslich. Ausbeute: 93%.



   Beispiel 3
14,5 g 6-Amino-2-methyl-2-heptanol, in 75 ml Chloroform gelöst, werden mit 24 g Theobromin-lessigsäure (hergestellt durch Reaktion von Theo  bromin-Natrium mit Natriummonochloracetat oder durch Oxydation von Theobromin-l-äthanol mit Kaliumpermanganat) versetzt. Unter Rühren und schwachem Erwärmen geht die Säure fast vollständig in Lösung. Das Chloroform wird abgedampft und der erhaltene dicke sirupartige Rückstand mit   Ather    gut durchgemischt. Das (6-Amino-2-methyl-2-heptanol)theobrominacetat scheidet sich als eine schneeweisse kristalline Masse aus, die, nach Trocknung im Vakuum bei   60     C, bei   149-150     schmilzt. Dieses Salz ist in Wasser mit neutraler Reaktion leicht löslich, wenig in Alkohol und praktisch unlöslich in Äther.



  Ausbeute: 34g = 90%.



   Beispiel 4
15,9 g   6-Methylamino -2- methyl-2-heptanol    und 24 g Theobrominessigsäure werden wie im Beispiel 3 reagieren gelassen. Man erhält das (6-Methylamino  2 -methyl-2 -heptanol)-theobrominacetat    als weisses, in Wasser mit neutraler Reaktion leicht lösliches kristallines Pulver. Ausbeute: 92%.



   Schmelzpunkt:   166-1690 C.      



  
 



  Process for the production of a new heart-acting salt
It is known from German patent specification No. 352980 that N-alkylcarboxylic acids of dialkylated xanthines produce neutral salts with a therapeutic effect which are readily soluble in water.



   On the other hand, it is known that amino alcohols with a tertiary hydroxyl group of the formula
EMI1.1
 where R is hydrogen or a methyl group, have interesting therapeutic properties as cardiotonics (Loubatieres A., Arch. int. pharmacodyn. 85, 333 L1951J, Robert P. Walton & Oliver J Brodie, Journ. of Pharmacol. & Exptl. Therapeutics, Vol . 96, No. 4, August 1949). The amino alcohols mentioned are liquids which form salts with various acids. In particular, the hydrochloride was used, which, however, has the disadvantage that it causes necrosis when injected in higher concentrations.



   It has now been found that the amino alcohols mentioned give salts dialkylated with N-alkyl carboxylic acids, which result in neutral solutions in water, which can also be injected in high concentrations without disadvantage, the two components of the salt known per se being a surprisingly favorable one result in therapeutic combination effects. This effect also occurs when administered orally.



   The salt formation can be carried out in the usual way by reacting the 6-amino-2-methyl-2-heptanol or



     6 -Methylamino-2-methyl-2 -heptanol with the N-alkylcarboxylic acid of a dialkylated xanthine in a suitable solvent such as ethanol or chloroform, preferably with gentle heating.



   The salts formed are new compounds with favorable application properties and excellent therapeutic effects.



   example 1
14.5 g of 6-amino-2-methyl-2-heptanol, dissolved in 100 ml of ethyl alcohol, are mixed with 24 g of theophylline-7acetic acid (prepared by reacting sodium theophyllinate with sodium monochloroacetate).



  The acid dissolves completely with stirring and gentle heating. The clear solution is left to stand at 0 "overnight; a fine, snow-white crystalline mass separates out, which, after filtration and washing with cold alcohol, is dried in vacuo at 600 ° C. Yield: 35 g = 91%.



   The (6-amino-2-methyl-2-heptanol) -theophylline acetate is a white crystalline, practically odorless powder. It is very easily soluble in water with a neutral reaction, sparingly soluble in alcohol and very little in ether.



   Melting point: 140-142 C (corr.).



   Example 2
15.9 g of 6-methylamino-2-methyl-2-heptanol and 24 g of theophyllinessetic acid are allowed to react as in Example 1. The (6-methylamino2-methyl-2-heptanol) -theophylline acetate is obtained as a white crystalline powder with a melting point of 114-116 C.



  The salt is easily soluble in water with a neutral reaction. Yield: 93%.



   Example 3
14.5 g of 6-amino-2-methyl-2-heptanol, dissolved in 75 ml of chloroform, are mixed with 24 g of theobromine-lessetic acid (prepared by reacting theobromine-sodium with sodium monochloroacetate or by oxidizing theobromine-l-ethanol with Potassium permanganate). With stirring and gentle heating, the acid dissolves almost completely. The chloroform is evaporated and the thick syrupy residue obtained is mixed well with ether. The (6-amino-2-methyl-2-heptanol) theobromine acetate separates out as a snow-white crystalline mass which, after drying in vacuo at 60 ° C., melts at 149-150. This salt is easily soluble in water with a neutral reaction, little in alcohol and practically insoluble in ether.



  Yield: 34g = 90%.



   Example 4
15.9 g of 6-methylamino -2-methyl-2-heptanol and 24 g of theobromine acetic acid are allowed to react as in Example 3. The (6-methylamino 2-methyl-2-heptanol) -theobromine acetate is obtained as a white crystalline powder which is easily soluble in water with a neutral reaction. Yield: 92%.



   Melting point: 166-1690 C.

 

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung von therapeutisch wirksamen Salzen, dadurch gekennzeichnet, dass man 6-Amino-2-methyl-2-heptanol oder 6-Methylamino2-methyl-2-heptanol mit einer N-Alkylcarbonsäure eines dialkylierten Xanthins umsetzt. PATENT CLAIM Process for the preparation of therapeutically active salts, characterized in that 6-amino-2-methyl-2-heptanol or 6-methylamino-2-methyl-2-heptanol is reacted with an N-alkyl carboxylic acid of a dialkylated xanthine. UNTERANSPRUCH Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass man als Xanthinderivat Theophyllin-7essigsäure oder Theobromin-l-essigsäure verwendet. UNDER CLAIM Process according to patent claim, characterized in that theophylline-7acetic acid or theobromine-1-acetic acid is used as the xanthine derivative.
CH8137559A 1959-12-02 1959-12-02 Process for the production of a new heart-acting salt CH373759A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH8137559A CH373759A (en) 1959-12-02 1959-12-02 Process for the production of a new heart-acting salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH8137559A CH373759A (en) 1959-12-02 1959-12-02 Process for the production of a new heart-acting salt

Publications (1)

Publication Number Publication Date
CH373759A true CH373759A (en) 1963-12-15

Family

ID=4538756

Family Applications (1)

Application Number Title Priority Date Filing Date
CH8137559A CH373759A (en) 1959-12-02 1959-12-02 Process for the production of a new heart-acting salt

Country Status (1)

Country Link
CH (1) CH373759A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2474502A1 (en) * 1980-01-28 1981-07-31 Chimie Synthese Sa Hept:aminol salt of hydroxy:ethyl-theophylline mono:succinate ester - useful in human and veterinary medicine for treating cardiovascular disorders
EP0172383A2 (en) * 1984-08-06 1986-02-26 Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. Pharmacologically active salt derivatives of 1,2,3,6-tetrahydro-1,3-dimethyl-2,6 dioxopurine-7-acetic acid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2474502A1 (en) * 1980-01-28 1981-07-31 Chimie Synthese Sa Hept:aminol salt of hydroxy:ethyl-theophylline mono:succinate ester - useful in human and veterinary medicine for treating cardiovascular disorders
EP0172383A2 (en) * 1984-08-06 1986-02-26 Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. Pharmacologically active salt derivatives of 1,2,3,6-tetrahydro-1,3-dimethyl-2,6 dioxopurine-7-acetic acid
EP0172383A3 (en) * 1984-08-06 1987-04-15 Ital Biochim Farm Lisapharma Pharmacologically active salt derivatives of 1,2,3,6-tetrahydro-1,3-dimethyl-2,6 dioxopurine-7-acetic acid

Similar Documents

Publication Publication Date Title
DE2212660C3 (en) Single optical isomers of binaphthylphosphoric acids, processes for separating a racemate therefrom and their use for separating racemic bases
CH555352A (en) Process for the preparation of (((OMEGA) -1) -OXOALKYL) -DIMETHYLXANTHINES.
DE214376C (en)
CH373759A (en) Process for the production of a new heart-acting salt
DE1966640B2 (en) PROCESS FOR PREPARING 4-HYDROXY- AND 4,6-DIHYDROXY-PYRAZOLO SQUARE CLAMP TO 3,4-D SQUARE CLAMP TO PYRIMIDINES
DE2166270C3 (en) Nicotinoylaminoethanesulfonyl-2amino-thiazole
AT299938B (en) Process for the preparation of the new sodium salt of (1-nicotinoyl-2-methyl-5-methoxy-3-indolyl) -acetic acid, optionally mixed with the free acid
DE1620479C3 (en) Xylitol pentanicotinate and its acid addition salts
AT276439B (en) Process for the production of new xylitol nicotinates
DE1924174C3 (en) Magnesium Orotate Glycinate
AT212304B (en) Process for the preparation of amino acid esters of threo-1- (p-nitrophenyl) -2-dichloroacetamidopropane-1,3-diols
AT217048B (en) Process for the preparation of new theophylline derivatives substituted in the 7-position
DE1593807C (en) alpha ascine methyl or ethy (ester, as well as a process for their production
DE557814C (en) Process for the preparation of N-substituted di- or polynuclear aminooxy compounds
AT266109B (en) Process for the preparation of the sodium salt of (1-p-chlorobenzoyl-2-methyl-5-methoxy-3-indolyl) -acetic acid, optionally mixed with the free acid
DE1670284C3 (en) Penicillins
DE896805C (en) Process for making a testosterone ester
AT220613B (en) Process for the preparation of the new 2- [1 ', 1'-diphenyl-propyl- (3') -amino] -3-phenyl-propane-gluconate
AT227707B (en) Process for the production of new quinazolinone derivatives
AT147483B (en) Process for the preparation of compounds of methyl N-methyltetrahydronicotinate.
AT158301B (en) Process for the production of vitamin B1.
AT225183B (en) Process for the preparation of phenylalanine derivatives
AT216524B (en) Process for the preparation of new theophylline derivatives
DE1643267B2 (en) 2,2,2-Trichloräthylglycinat and process for its preparation
DE1058031B (en) Production of essentially anhydrous hydrazine from aqueous hydrazine hydrate solutions